Market Pulse Archives

Dec. 27, 2010, 9:36 a.m. EST

Alimera, pSivida crushed by FDA setback

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Alimera Sciences Inc. (ALIM)

or Cancel Already have a watchlist? Log In

By Val Brickates Kennedy

ALIM

BOSTON (MarketWatch) -- Shares of partners Alimera Sciences /zigman2/quotes/205266417/composite ALIM -2.17% and pSivida Corp. plunged almost 20% early Monday on news that the U.S. Food and Drug Administration has refused to approve their drug Iluvien for the treatment of diabetic macular edema. In a statement released late Thursday, the companies said that while the FDA is withholding approval pending the submission of additional clinical analyses, it is not requiring the companies to run more clinical trials. Alimera licenses Iluvien from pSivida, which will receive royalties on product sales if and when Iluvien is approved.

/zigman2/quotes/205266417/composite
US : U.S.: Nasdaq
$ 6.77
-0.15 -2.17%
Volume: 10,587
Aug. 11, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$48.46 million
Rev. per Employee
$341,649
loading...

Get news alerts on Alimera Sciences Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

World News from MarketWatch

Link to MarketWatch's Slice.